Stock Events

Stock Events

Delcath Systems 

$16.48
66
+$0.00+0% Friday 20:00
+$0.02+0.12%Friday 22:05After hours

Statistics

Day High
16.48
Day Low
16.46
52W High
17.42
52W Low
8.12
Volume
5,339
Avg. Volume
-
Mkt Cap
571.84M
P/E Ratio
1,301
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.11
-0.05
0.01
0.07
Expected EPS
-0.092
Actual EPS
N/A

Financials

3.17%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
85.23MRevenue
2.7MNet Income

Analyst Ratings

26.50Average Price Target
The highest estimate is 32.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DCTH. It's not an investment recommendation.
Tesla
16
TSLA
Amazon
16
AMZN
AMD
16
AMD
NVIDIA
15
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
BlackRock Technology and Private Equity Term Trust
BTX
Mkt Cap1.01B
BioTime, Inc. focuses on developing and commercializing products in the field of regenerative medicine and blood filtration, directly competing with Delcath's cancer treatment technologies.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its subsidiary Janssen Pharmaceuticals, develops treatments for various cancers, competing with Delcath's hepatic delivery systems.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol-Myers Squibb Company offers a range of cancer treatments, including therapies that could be seen as alternatives to Delcath's percutaneous hepatic perfusion.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. has a strong portfolio in oncology, including therapies that could compete with Delcath's methods for treating liver cancers.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. develops and markets drugs for various cancer types, potentially competing with Delcath's targeted liver cancer treatments.
Novartis
NVS
Mkt Cap292.35B
Novartis AG has a broad oncology segment that includes treatments for liver cancer, posing competition to Delcath's specialized procedures.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie Inc. engages in the discovery and marketing of a range of oncology treatments, which could serve as alternatives to Delcath's technology.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc. offers therapies for liver diseases, including cancer, which could compete with Delcath's liver-directed therapies.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc. has a diverse oncology portfolio, including treatments that could compete with Delcath's approach to cancer treatment.

About

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Show more...
CEO
Gerard J. Michel
Employees
156
Country
United States
ISIN
US24661P8077
WKN
000A2PT5P

Listings

XNAS
US
DCTH
STU
DE
DV3R.STU
MU
DE
DV3R.MU
F
DE
DV3R.F

0 Comments

Share your thoughts

FAQ

What is Delcath Systems stock price today?▼
The current price of DCTH is $16.48 USD — it has increased by +0% in the past 24 hours. Watch Delcath Systems stock price performance more closely on the chart.
What is Delcath Systems stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Delcath Systems stocks are traded under the ticker DCTH.
Is Delcath Systems stock price growing?▼
DCTH stock has risen by +0.86% compared to the previous week, the month change is a +30.48% rise, over the last year Delcath Systems has showed a +41.46% increase.
What is Delcath Systems market cap?▼
Today Delcath Systems has the market capitalization of 571.84M
When is the next Delcath Systems earnings date?▼
Delcath Systems is going to release the next earnings report on November 10, 2026.
What were Delcath Systems earnings last quarter?▼
DCTH earnings for the last quarter are 0.07 USD per share, whereas the estimation was -0.09 USD resulting in a +178.53% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Delcath Systems revenue for the last year?▼
Delcath Systems revenue for the last year amounts to 85.23M USD.
What is Delcath Systems net income for the last year?▼
DCTH net income for the last year is 2.7M USD.
How many employees does Delcath Systems have?▼
As of September 05, 2026, the company has 156 employees.
In which sector is Delcath Systems located?▼
Delcath Systems operates in the Health & Wellness sector.
When did Delcath Systems complete a stock split?▼
The last stock split for Delcath Systems was on December 24, 2019 with a ratio of 1:700.
Where is Delcath Systems headquartered?▼
Delcath Systems is headquartered in QUEENSBURY, United States.